This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Helge Zieler, PhD
Founder & President at Primordial Genetics

Profile

Helge is a biotechnology professional and entrepreneur with >20 years of industry experience in technology development, R&D project leadership and IP development/management in early-stage biotechnology companies. He has a passion for early-stage genetic technologies, and has helped launch the operations of multiple biotechnology startups. Helge did his doctorate work in yeast molecular genetics in Nobel Laureate Paul Berg’s laboratory at Stanford University’s Biochemistry Department and received his PhD in 1994. Following an interest in malaria research he then did his post-doctoral work in the Laboratory of Parasitic Diseases at the National Institutes of Health. Starting in 2000, Helge worked on a variety of projects in crop plant biotechnology and genomics. He led a group at Chromatin Inc that successfully developed artificial chromosomes as gene delivery vehicles in multiple crop species. As Senior Director for Plant Genomics at Synthetic Genomics Inc, he spearheaded efforts to sequence the oil palm and jatropha genomes and set up a molecular breeding project for castor improvement, while also participating in metagenomic studies of microbial populations in subsurface hydrocarbons. Helge founded Primordial Genetics in 2011 with the goal of developing a novel whole-genome genetic technology for improving the performance of microbes and enzymes. The company launched its laboratory operations in 2013 and, following two years of technology development, focused on developing manufacturing systems for nucleic acids used in therapeutic s, diagnostics and R&D products. Helge's background combines strong technical skills in molecular biology, genomics, plant and algal biotechnology and synthetic biology with entrepreneurism and R&D project leadership.

Agenda Sessions

  • High-efficiency Nucleic Acid Manufacturing Systems to Fulfil the Promise of Genomic Medicine

    16:00